Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CAR-T Indication-Based Pricing May Be Evaluated In Medicare Demo

Executive Summary

Novartis exec discusses details around its agreements with CMS for outcomes based payments and indication-based pricing for Kymriah.

You may also be interested in...



CMS' Verma Touts Value-Based Payments After Cancellation Of Pilot For Novartis' Kymriah

'It's not for every medication,' CMS administrator says, but agency continues to explore how to apply value-based pricing.

CAR-T Reimbursement Threatened By Medicare Coverage Analysis, Manufacturers Say

Novartis, Gilead/Kite and Celgene protest the US Centers for Medicare and Medicaid Services’ decision to launch a Medicare coverage analysis for CAR-T drugs because it might lead to coverage restrictions.

Pricing Positives From Trump Plan Include Potential 340B Changes, Value-Based Contracts

Industry should be encouraged by Blueprint's interest in examining impact of Medicaid rebates, the annual excise tax, and the 340B program. Document also confirms Administration’s interest in value-based contracting.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS121853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel